OTCM
BXRXQ
Market cap0kUSD
Jun 02, Last price
0.00USD
Name
Baudax Bio Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-44.81%
Rev. gr., 5y
0.00%
Revenues
1m
+17.50%
Net income
-59m
L+197.41%
CFO
-28m
L-43.59%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Baudax Bio, Inc. is a pharmaceutical enterprise dedicated to creating and marketing therapeutic solutions for inpatient and urgent care environments. Their flagship commercial offering is ANJESO, an injectable meloxicam formulation designed to alleviate moderate to severe pain, which can be administered independently or in conjunction with non-NSAID pain medications. The company's research and development portfolio features several candidates: BX1000, an intermediate-acting neuromuscular blocker currently in Phase II trials; BX2000, an ultra-short-acting variant of the same class, undergoing Phase I investigation; BX3000, an agent intended to reverse neuromuscular blockade; and Dex-IN, a unique intranasal delivery system for dexmedetomidine. Founded in 2019, the firm operates from its base in Malvern, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||